COLUMVI

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Israel, Lithuania, Romania, UK.

Active ingredients

The drug COLUMVI contains one active pharmaceutical ingredient (API):

1	Glofitamab UNII 06P3KLK2J8 - GLOFITAMAB
	Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T cells. By simultaneous binding to CD20 on the B cell and CD3 on the T cell, glofitamab mediates the formation of an immunological synapse with subsequent T-cell activation and proliferation, secretion of cytokines and release of cytolytic proteins that results in the lysis of CD20-expressing B cells.
	Read more about Glofitamab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COLUMVI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX28		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX28

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02536552, 02536560
EE	Ravimiamet	1898758, 1898769
FR	Base de données publique des médicaments	66831305, 68364042
IL	מִשְׂרַד הַבְּרִיאוּת	21017, 21018
LT	Valstybinė vaistų kontrolės tarnyba	1097398, 1097399
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69689001, W69690001
US	FDA, National Drug Code	50242-125, 50242-127